Medicinal chemistry aspects of drug targets in sphingolipid metabolism.
Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Brunner Strasse 59, 1235 Vienna, Austria. peter.nussbaumer@novartis.com
Peter
P
Nussbaumer
D000446:Aldehyde-Lyases / Q000037:antagonists & inhibitors; D000581:Amidohydrolases / Q000037:antagonists & inhibitors; D000818:Animals; D055572:Ceramidases; D002626:Chemistry, Pharmaceutical; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008565:Membrane Proteins / Q000037:antagonists & inhibitors; D010744:Phosphoric Monoester Hydrolases / Q000037:antagonists & inhibitors; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000037:antagonists & inhibitors; D013107:Sphingolipids / Q000378:metabolism*; D013108:Sphingomyelin Phosphodiesterase / Q000037:antagonists & inhibitors; D000099157:Sphingosine Kinase
D000446:Aldehyde-Lyases; D000581:Amidohydrolases; D055572:Ceramidases; D004791:Enzyme Inhibitors; D008565:Membrane Proteins; D010744:Phosphoric Monoester Hydrolases; D017853:Phosphotransferases (Alcohol Group Acceptor); D013107:Sphingolipids; D013108:Sphingomyelin Phosphodiesterase; D000099157:Sphingosine Kinase; C066324:ceramide kinase; C401298:sphingosine-1-phosphate phosphatase; C022649:sphingosine 1-phosphate lyase (aldolase)